Showing 2281-2290 of 5554 results for "".
- Opzelura Helps Beat AD Itchhttps://practicaldermatology.com/news/opzelura-helps-beat-ad-itch/2461690/Opzelura (ruxolitinib) cream 1.5% showed substantial and rapid itch reduction in patients with mild-moderate Atopic Dermatitis (AD). These data were featured in a poster presentation at the Revolutionizing Atopic Dermatitis (RAD) Conference, held from April 29-May 1 in Washing
- Lilly's Lebrikizumab Improves AD on Face, Handshttps://practicaldermatology.com/news/lillys-lebrikizumab-improves-ad-on-face-hands/2461689/Up to 73% of atopic dermatitis patients (AD) receiving lebrikizumab showed Improved or cleared skin on face or hands at 16 weeks, a new study shows. Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients 12 y
- Meet Zerigo 2.0: Upgraded System Allows Patients to Better Manage Psoriasis and Eczema at Homehttps://practicaldermatology.com/news/meet-zerigo-20-upgraded-system-allows-patients-to-better-manage-psoriasis-and-eczema-at-home-2/2461681/Zerigo Health is rolling out the Zerigo 2.0 ecosystem, the newest iteration of its digital health platform for the treatment and management of chronic skin conditions like eczema and psoriasis to employers, health plans, and their provide
- Skin Cancer Foundation Hits the Road: Destination Healthy Skin Program Kicks Off on May 6, 2023https://practicaldermatology.com/news/skin-cancer-foundation-hits-the-road-destination-healthy-skin-program-kicks-off-on-may-6-2023/2461669/The Skin Cancer Foundation will launch its annual mobile education and screening program, Destination Healthy Skin, on Saturday, May 6, in Greenwich, Connecticut. The program educates the public about the importance of skin cancer early detection and effective sun p
- ASA Honors Dr. Mark G. Lebwohl, Leo Pharmahttps://practicaldermatology.com/news/asa-honors-dr-mark-g-lebwohl-leo-pharma/2461652/Mark G. Lebwohl, MD and LEO Pharma received honors at the American Skin Association’s (ASA) annual Spring Gala, "We were proud to honor Dr. Mark Lebwohl and LEO Pharma for their dedication to the field of dermatology. Both honorees share in ASA
- Analysis Reveals How Incurable Skin Cancer Resists Treatmenthttps://practicaldermatology.com/news/research-autopsies-reveals-how-incurable-skin-cancer-resists-treatment/2461637/A new analysis published in the journal Cancer Discovery reveals how some skin cancers stop responding to treatment at the end of l
- FDA Approves Humira Biosimilar Hyrimozhttps://practicaldermatology.com/news/fda-approves-humira-biosimilar-hyrimoz/2461636/The FDA approved a citrate-free high-concentration formulation (HCF) of Hyrimoz (adalimumab-adaz; Sandoz) injection, a biosimilar to Humira (adalimumab). The adalimumab citrate-free HCF (100 mg/mL) is approved to treat seven indications covered by the reference medicine, Humira, in
- Study: Atopic Asthma/Eczema Linked to Heightened Risk of Osteoarthritishttps://practicaldermatology.com/news/study-atopic-asthmaeczema-linked-to-heightened-risk-of-osteoarthritis/2461635/People with atopic diseases like asthma or eczema may be at heightened risk of osteoarthritis, according to research published online in the Annals of the Rheumatic Diseases. Drugs used to dampen d
- Aquavit Files Additional IND for New Toxin for Palmar Hyperhidrosishttps://practicaldermatology.com/news/aquavit-files-additional-ind-for-new-toxin-for-palmar-hyperhidrosis/2461625/Aquavit Holdings is asking the US Food and Drug Administration for an additional IND for DTX-024, a treatment of palmar hyperhidrosis using the company’s patented microchannel technology. DTX-024 is a highly purified and clinically tested injectable neuromodulator derived fr
- Metal Implants May Cause Nickel Hypersensitivityhttps://practicaldermatology.com/news/metal-implants-may-cause-nickel-hypersensitivity/2461614/Dermatologists are seeing more patients concerned about a possible skin hypersensitivity to the nickel or other metals used in implanted medical devices. Millions of people in the U.S. report having a metal allergy, and current estimates state that 10 percent of Americans will receive a